J Urol Oncol > Volume 21(2); 2023 > Article |
|
Characteristic |
BPT (n=30) |
RC (n=45) | p-value‡ | |
---|---|---|---|---|
RT (n=22) | CCRT (n=8) | |||
Age (yr) | 68.9±11.4 | 64.6±4.9 | 68.8±7.9 | 0.635 (0.975) |
Sex | 0.594 (0.806) | |||
Female | 7 (31.8) | 0 (0) | 13 (28.9) | |
Male | 15 (68.2) | 8 (100.0) | 32 (71.1) | |
UTUC T stage | 0.009 (0.052) | |||
1 | 3 (13.6) | 0 (0) | 19 (42.2) | |
2 | 7 (31.8) | 3 (37.5) | 12 (26.7) | |
3 | 12 (54.5) | 5 (62.5) | 14 (31.1) | |
UTUC N stage | 0.520 (0.418) | |||
0 | 20 (90.9) | 8 (100) | 43 (95.6) | |
1 | 0 (0) | 0 (0) | 1 (2.2) | |
2 | 1 (4.5) | 0 (0) | 1 (2.2) | |
3 | 1 (4.5) | 0 (0) | 0 (0) | |
UTUC location | 0.163 (0.188) | |||
Renal pelvis | 8 (36.4) | 4 (50.0) | 26 (57.8) | |
Ureter | 7 (31.8) | 3 (37.5) | 7 (15.6) | |
Both | 7 (31.8) | 1 (12.5) | 12 (26.7) | |
Time to MIBC diagnosis (mo)* | 24.8 (8.6-42.5) | 25.9 (8.6-43.2) | 19.8 (9.2-38.6) | 0.725 (0.931) |
eGFR† | 55.3±16.4 | 54.0±15.7 | 48.6±20.0 | 0.194 (0.148) |
MIBC T | 0.001 (0.002) | |||
2 | 9 (40.9) | 2 (25.0) | 34 (75.6) | |
3 | 11 (50.0) | 4 (50.0) | 5 (11.1) | |
4 | 2 (9.1) | 2 (25.0) | 6 (13.3) | |
MIBC N | 0.226 (0.537) | |||
0 | 17 (77.3) | 5 (62.5) | 40 (88.9) | |
1 | 1 (4.5) | 1 (12.5) | 1 (2.2) | |
2 | 3 (13.6) | 2 (25.0) | 2 (4.4) | |
3 | 1 (4.5) | 0 (0) | 2 (4.4) |
Variables are presented as mean±standard deviation, number (%), or median (interquartile range).
BPT, bladder-preserving therapy; RT, radiation therapy; CCRT, concurrent chemoradiotherapy; RC, radical cystectomy; UTUC, upper tract urothelial carcinoma; MIBC, muscle-invasive bladder cancer; eGFR, estimated glomerular filtration rate.
Youngheun Jo
https://orcid.org/0000-0002-5604-9781
Jun Seok Kim
https://orcid.org/0000-0003-4384-7124
Yoo Sub Shin
https://orcid.org/0009-0005-5075-1843
Jongchan Kim
https://orcid.org/0000-0002-0022-6689
Won Sik Jang
https://orcid.org/0000-0002-9082-0381
Jee Soo Park
https://orcid.org/0000-0001-9976-6599
Won Sik Ham
https://orcid.org/0000-0003-2246-8838